Chemistry:Garsorasib
From HandWiki
Garsorasib is a pharmaceutical drug used for cancer treatment. It is a selective inhibitor of the enzyme KRAS that has the G12C mutation.[1][2]
In China, it is approved for the treatment of advanced non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation in patients who have received at least one systemic treatment.[3]
References
- ↑ "Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation". Signal Transduction and Targeted Therapy 10 (1). June 2025. doi:10.1038/s41392-025-02274-z. PMID 40523897.
- ↑ "Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial". The Lancet. Respiratory Medicine 12 (8): 589–598. August 2024. doi:10.1016/S2213-2600(24)00110-3. PMID 38870979.
- ↑ "Garsorasib Tablets Approved with Conditions for Marketing by China NMPA". National Medical Products Administration. 2025-02-19. https://english.nmpa.gov.cn/2025-02/19/c_1073662.htm.
 |  |
